Suzhou Basecare Medical (2170) Fundamentals 2026 — Revenue Analysis | SniperIQ
Suzhou Basecare Medical (2170) is a CN-listed Healthcare company in Medical - Devices with a market capitalization of HK
Suzhou Basecare Medical (2170) is a CN-listed Healthcare company in Medical - Devices with a market capitalization of HK
Suzhou Basecare Medical (2170) has a market capitalization of approximately HK
Suzhou Basecare Medical's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Suzhou Basecare Medical runs a net profit margin of -95.8%, a gross margin of 53.0%, and an operating margin of -91.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Suzhou Basecare Medical reported revenue of ¥233M for fiscal year 2025, with net income of -¥223M and earnings per share (EPS) of -0.82. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Suzhou Basecare Medical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Suzhou Basecare Medical carries a debt-to-equity ratio of 0.37x and a current ratio of 3.98x, with a market beta of 0.01. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Suzhou Basecare Medical (2170) the key facts are: market cap HK
Get Suzhou Basecare Medical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.